NCT03325036已完成不适用
Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy: Quantitative Analysis and Prognostic Implication
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Disease progression
研究概览
简要总结
The purpose of the study is to investigate the clinical usefulness of serum levels of immunologic profiles including pro/anti-inflammatory interleukins, other detectable serum biomarkers including transforming growth factor b1 (TGFb1) or soluble major histocompatibility complex Class I chain-related peptide A (sMICA), and leukocyte subpopulations in head and neck cancers patients receiving curative radiotherapy, as prognostic biomarkers for disease recurrence and survival.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with head and neck cancer receiving curative radiotherapy in NTUH radiation therapy department.
排除标准
- •Patients with head and neck cancer NOT receiving curative radiotherapy in NTUH radiation therapy department.
结局指标
主要结局
Disease progression
时间窗: Three years
Tumor local recurrence or distant metastasis
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Biomarkers in Patients With Head and Neck Cancer and in Healthy VolunteersHead and Neck CancerNCT00899769Vanderbilt University Medical Center100
招募中
不适用
Immune Biomarker Study for Head and Neck CancerHead and Neck CancerOral Cavity CancerHypopharyngeal CancerLaryngeal CancerOropharyngeal CancerNCT05375266University of Erlangen-Nürnberg Medical School1,100
已完成
不适用
Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio)Head and Neck CancerNCT02059668Technische Universität Dresden588
已完成
不适用
Evaluation of Subcutaneous Immunotherapy Towards Pollen in ChildrenRhinitis, AllergicConjunctivitis, AllergicAsthmaNCT03375775Karolinska Institutet40
撤回
不适用
Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell CancerHead and Neck Squamous Cell CarcinomaNCT05296135Cofactor Genomics, Inc.40